Evotaz

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

cobicistat, atazanavir

Available from:

Bristol-Myers Squibb Pharma EEIG

ATC code:

J05AR15

INN (International Name):

atazanavir, cobicistat

Therapeutic group:

Antivirusi za sistemsko uporabo

Therapeutic area:

Okužbe z virusom HIV

Therapeutic indications:

EVOTAZ is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 in 5.

Product summary:

Revision: 14

Authorization status:

Pooblaščeni

Authorization date:

2015-07-13

Patient Information leaflet

                                52
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Bristol-Myers Squibb Pharma EEIG
Plaza 254
Blanchardstown Corporate Park 2
Dublin 15, D15 T867
Irska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/15/1025/001 30 filmsko obloženih tablet
EU/1/15/1025/002 90 (3 plastenke po 30) filmsko obloženih tablet
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
evotaz
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
53
B. NAVODILO ZA UPORABO
54
NAVODILO ZA UPORABO
EVOTAZ 300 MG/150 MG FILMSKO OBLOŽENE TABLETE
atazanavir/kobicistat
PRED ZAČETKOM JEMANJA ZDRAVILA NATANČNO PREBERITE NAVODILO, KER
VSEBUJE ZA VAS POMEMBNE
PODATKE!

Navodilo shranite. Morda ga boste želeli ponovno prebrati.

Če imate dodatna vprašanja, se posvetujte z zdravnikom ali
farmacevtom.

Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
Njim bi lahko celo
škodovalo, čeprav imajo znake bolezni, podobne vašim.

Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom
ali farmacevtom. Posvetujte
se tudi, če opazite katere koli neželene učinke, ki niso navedeni v
tem navodilu. Glejte
poglavje 4.
KAJ VSEBUJE NAVODILO
1.
Kaj je zdravilo EVOTAZ in za kaj ga uporabljamo
2.
Kaj morate vedeti, preden boste vzeli zdravilo EVOTAZ
3.
Kako jemati zdravilo EVOTAZ
4.
Možni neželeni učinki
5.
Shranjevanje zdravila EVOTAZ
6.
Vsebina pakiranja in dodatne informacije
1.
KAJ JE ZDRAVILO EVOTAZ IN ZA KAJ GA UPORABLJAMO
Zdravilo EVOTAZ vsebuje dve učinkovini:

ATAZANAVIR, KI DELUJE PROTI VIRUSOM (ALI RETROVIRUSOM).
Spada v skupino
_zaviralcev proteaz_
.
Ta zdravila delujejo na okužbo z virusom humane imunske
pomanjkljivosti (HIV) tako, da
zavrejo nastajanje beljakovine, ki jo virus HIV pot
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
EVOTAZ 300 mg/150 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena filmsko obložena tableta vsebuje atazanavirjev sulfat v
količini, ki ustreza 300 mg atazanavirja, in
150 mg kobicistata.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta
Rožnata, ovalna, obojestransko izbočena, filmsko obložena tableta,
velika približno 19 mm x
10,4 mm, z oznako “3641” na eni in brez oznak na drugi strani.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo EVOTAZ je v kombinaciji z drugimi protiretrovirusnimi
zdravili indicirano za zdravljenje
odraslih in mladostnikov (starih 12 let in starejših, s telesno maso
najmanj 35 kg), okuženih z virusom
HIV-1, brez znanih mutacij, povezanih z odpornostjo proti atazanavirju
(glejte poglavji 4.4 in 5.1).
4.2
ODMERJANJE IN NAČIN UPORABE
Zdravljenje mora uvesti zdravnik, ki ima izkušnje z zdravljenjem
okužbe z virusom HIV.
Odmerjanje
_ _
Priporočeni odmerek zdravila EVOTAZ za odrasle in mladostnike (stare
12 let in starejše, s telesno
maso najmanj 35 kg) je ena tableta enkrat na dan. Bolnik jo vzame
peroralno skupaj s hrano (glejte
poglavje 5.2).
_Nasvet v primeru izpuščenih odmerkov_
Če je bolnik pozabil vzeti predpisani odmerek zdravila EVOTAZ ob
običajnem času in od tega še ni
minilo več kot 12 ur, mora pozabljeni odmerek zdravila EVOTAZ vzeti
skupaj s hrano takoj, ko je to
mogoče. Če pa je bolnik pozabil vzeti odmerek zdravila EVOTAZ ob
običajnem času in je od tega
minilo že več kot 12 ur, pozabljenega odmerka ne sme vzeti.
Nadaljevati mora le z jemanjem zdravila
ob običajnem času.
Posebne populacije
_ _
_Okvara ledvic _
Pri bolnikih z okvaro ledvic posebni previdnostni ukrepi niso potrebni
in odmerka zdravila EVOTAZ
ni treba posebej prilagajati, saj je izločanje kobicistata in
atazanavirja preko ledvic zelo omejeno.
Pri bolnikih, ki se zdravijo s hemodializo, uporaba zdravila EVOTAZ ni
priporočljiva (glejt
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 25-04-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 25-04-2023
Public Assessment Report Public Assessment Report Bulgarian 07-10-2023
Patient Information leaflet Patient Information leaflet Spanish 25-04-2023
Public Assessment Report Public Assessment Report Spanish 07-10-2023
Patient Information leaflet Patient Information leaflet Czech 25-04-2023
Public Assessment Report Public Assessment Report Czech 07-10-2023
Patient Information leaflet Patient Information leaflet Danish 25-04-2023
Public Assessment Report Public Assessment Report Danish 07-10-2023
Patient Information leaflet Patient Information leaflet German 25-04-2023
Public Assessment Report Public Assessment Report German 07-10-2023
Patient Information leaflet Patient Information leaflet Estonian 25-04-2023
Public Assessment Report Public Assessment Report Estonian 07-10-2023
Patient Information leaflet Patient Information leaflet Greek 25-04-2023
Public Assessment Report Public Assessment Report Greek 07-10-2023
Patient Information leaflet Patient Information leaflet English 25-04-2023
Public Assessment Report Public Assessment Report English 10-08-2015
Patient Information leaflet Patient Information leaflet French 25-04-2023
Public Assessment Report Public Assessment Report French 07-10-2023
Patient Information leaflet Patient Information leaflet Italian 25-04-2023
Public Assessment Report Public Assessment Report Italian 07-10-2023
Patient Information leaflet Patient Information leaflet Latvian 25-04-2023
Public Assessment Report Public Assessment Report Latvian 07-10-2023
Patient Information leaflet Patient Information leaflet Lithuanian 25-04-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 25-04-2023
Public Assessment Report Public Assessment Report Lithuanian 07-10-2023
Patient Information leaflet Patient Information leaflet Hungarian 25-04-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 25-04-2023
Public Assessment Report Public Assessment Report Hungarian 07-10-2023
Patient Information leaflet Patient Information leaflet Maltese 25-04-2023
Public Assessment Report Public Assessment Report Maltese 07-10-2023
Patient Information leaflet Patient Information leaflet Dutch 25-04-2023
Public Assessment Report Public Assessment Report Dutch 07-10-2023
Patient Information leaflet Patient Information leaflet Polish 25-04-2023
Public Assessment Report Public Assessment Report Polish 07-10-2023
Patient Information leaflet Patient Information leaflet Portuguese 25-04-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 25-04-2023
Public Assessment Report Public Assessment Report Portuguese 07-10-2023
Patient Information leaflet Patient Information leaflet Romanian 25-04-2023
Public Assessment Report Public Assessment Report Romanian 07-10-2023
Patient Information leaflet Patient Information leaflet Slovak 25-04-2023
Public Assessment Report Public Assessment Report Slovak 07-10-2023
Patient Information leaflet Patient Information leaflet Finnish 25-04-2023
Public Assessment Report Public Assessment Report Finnish 07-10-2023
Patient Information leaflet Patient Information leaflet Swedish 25-04-2023
Public Assessment Report Public Assessment Report Swedish 07-10-2023
Patient Information leaflet Patient Information leaflet Norwegian 25-04-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 25-04-2023
Patient Information leaflet Patient Information leaflet Icelandic 25-04-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 25-04-2023
Patient Information leaflet Patient Information leaflet Croatian 25-04-2023
Public Assessment Report Public Assessment Report Croatian 07-10-2023

Search alerts related to this product

View documents history